Denali Therapeutics Inc.
NASDAQ:DNLI
Overview | Financials
Company Name | Denali Therapeutics Inc. |
Symbol | DNLI |
Currency | USD |
Price | 29.6 |
Market Cap | 4,237,684,000 |
Dividend Yield | 0% |
52-week-range | 14.56 - 32.132 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ryan J. Watts Ph.D. |
Website | https://www.denalitherapeutics.com |
An error occurred while fetching data.
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD